A phase I trial for advanced esophageal squamous cell carcinoma in patients with HLA-A*2402 demonstrated that a combination of LY6K and TTK with CpG-7909 elicited potent LY6K-specific T cell responses. This evidence concerns the gene LY6K and esophageal squamous cell carcinoma.